Overview

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy and safety of TLN-232 used to treat patients with metastatic melanoma that recur/progress after receiving first line systemic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Thallion Pharmaceuticals